Home Tags CDMO

Tag: CDMO

Bioconjugation Technology Selection during Early-Stage Development – A Strategy to Streamline...

Abstract Bioconjugate therapeutics comprise a fast-growing class of drugs with applications in various disease areas. In the past years, particularly antibody-drug conjugates (ADCs) have undergone...

A Fantastic Voyage: From Magic Bullet to Antibody-drug Conjugate

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer (and potentially other diseases). However, unlike chemotherapy, ADCs are intended to directly target and kill tumor cells while, at the same time sparing normal, healthy cells.
ADC Bio's PD Lab

Opportunities for ADC Development and Manufacturing

At the 2022 World ADC Conference in San Diego, Stewart Mitchell, Executive Vice President and site head of Sterling Pharma Solutions' Deeside, U.K. facility, presented a case study on the development and GMP manufacture at the site.

A New Horizon in ADC Technology: A Panel Discussion

Targeted therapies such as antibody-drug conjugates (ADC) have opened new ways in targeting diseases like cancer and hematological malignancies. High-potent active pharmaceutical ingredients, also...

MilliporeSigma: New Innovation and Capacity to Advance Next Generation Antibody-drug Conjugate...

With the approval of new antibody-drug conjugates (ADC), the global market size for ADCs, valued at USD 4.3 billion in 2020, is expected to...

How a CDMO can Support ADC Manufacturing

Over the last decades, outsourcing of pharmaceutical development and manufacturing, driven by a variety of factors, has resulted in the growth of Contract Development...

MabPlex awards CloudWorks4All with Enterprise Resource Planning (ERP) Contract

MabPlex USA, the North American subsidiary, China-based MabPlex (Yantai, Shandong Province, China) has contracted systems integrator CloudWorks4All, a leading life science and cloud ERP...

Lonza to Provide Customer-Dedicated Suites for Commercialization of Bioconjugates

Lonza, in a statement, confirmed signing a strategic collaboration for bioconjugation with a global biopharma company. Under the terms of the agreement, Lonza will construct...

Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement

Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO) and San Francisco-based biotech Bolt Bioterapeutics have signed a production agreement in which Piramal...
Ajinomoto Bio-Pharma Services has established a high-containment bioconjugate manufacturing facility for the production and fill and finish of Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC). The facility, developed by SKAN AG, has been designed for safe handling and manipulation of very low OEL compounds (down to 1 ng/m3) while maintaining aseptic conditions and cGMP compliance. Photo courtesy: © 2020 Ajinomoto Bio-Pharma.

Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality...

Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies...

X